Compare Stocks: CVKD, AYTU, CLRB, and TVRD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.29 +0.4%	$2.24	$1.65 ▼ $3.07	$24.47M	0.26	28,137 shs	20,139 shs
CLRB Cellectar Biosciences	$2.35 -3.3%	$2.58	$2.20 ▼ $6.52	$22.97M	0.56	29,492 shs	69,220 shs
CVKD Cadrenal Therapeutics	$1.28 -3.8%	$2.17	$1.27 ▼ $14.64	$4.74M	1.82	1.17 million shs	167,747 shs
TVRD Tvardi Therapeutics	$1.85 -1.6%	$2.27	$1.50 ▼ $43.65	$25.08M	0.32	177,628 shs	97,203 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	+0.44%	+2.23%	+3.62%	+1.78%	-2.14%
CLRB Cellectar Biosciences	-3.29%	-7.48%	-8.20%	-9.27%	-50.84%
CVKD Cadrenal Therapeutics	-3.76%	-18.21%	-36.95%	-71.17%	-90.05%
TVRD Tvardi Therapeutics	-1.60%	+2.78%	-8.87%	-35.99%	-93.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.29 +0.4%	$2.24	$1.65 ▼ $3.07	$24.47M	0.26	28,137 shs	20,139 shs
CLRB Cellectar Biosciences	$2.35 -3.3%	$2.58	$2.20 ▼ $6.52	$22.97M	0.56	29,492 shs	69,220 shs
CVKD Cadrenal Therapeutics	$1.28 -3.8%	$2.17	$1.27 ▼ $14.64	$4.74M	1.82	1.17 million shs	167,747 shs
TVRD Tvardi Therapeutics	$1.85 -1.6%	$2.27	$1.50 ▼ $43.65	$25.08M	0.32	177,628 shs	97,203 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	+0.44%	+2.23%	+3.62%	+1.78%	-2.14%
CLRB Cellectar Biosciences	-3.29%	-7.48%	-8.20%	-9.27%	-50.84%
CVKD Cadrenal Therapeutics	-3.76%	-18.21%	-36.95%	-71.17%	-90.05%
TVRD Tvardi Therapeutics	-1.60%	+2.78%	-8.87%	-35.99%	-93.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	2.25	Hold	$10.75	369.43% Upside
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	368.09% Upside
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	915.63% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	872.97% Upside

Current Analyst Ratings Breakdown

Latest CVKD, AYTU, CLRB, and TVRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$66.38M	0.37	$0.38 per share	6.07	$2.11 per share	1.09
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$3.16 per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.15 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	3.46	N/A	N/A	$0.63 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	9.16	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$2.79	N/A	N/A	N/A	N/A	-145.40%	-91.11%	N/A

Latest CVKD, AYTU, CLRB, and TVRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	Q4 2026	AYTU Aytu BioPharma	-$0.29	N/A	N/A	N/A	$12.28 million	N/A
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.12	1.00
CLRB Cellectar Biosciences	N/A	6.66	6.66
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
TVRD Tvardi Therapeutics	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
CLRB Cellectar Biosciences	16.41%
CVKD Cadrenal Therapeutics	7.92%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	4.90%
CLRB Cellectar Biosciences	2.58%
CVKD Cadrenal Therapeutics	14.59%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	10.73 million	10.21 million	Not Optionable
CLRB Cellectar Biosciences	10	9.45 million	9.21 million	No Data
CVKD Cadrenal Therapeutics	4	3.57 million	3.05 million	Not Optionable
TVRD Tvardi Therapeutics	80	13.34 million	12.35 million	N/A

CVKD, AYTU, CLRB, and TVRD Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen

August 30, 2026 | americanbankingnews.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

August 26, 2026 | globenewswire.com

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14, 2026 | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026 | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, AYTU, CLRB, and TVRD Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.29 +0.01 (+0.44%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$2.28 0.00 (-0.22%)

As of 06:44 AM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Cellectar Biosciences NASDAQ:CLRB

$2.35 -0.08 (-3.29%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$2.40 +0.05 (+2.13%)

As of 09:15 AM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cadrenal Therapeutics NASDAQ:CVKD

$1.28 -0.05 (-3.76%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.27 -0.01 (-0.39%)

As of 09:05 AM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Tvardi Therapeutics NASDAQ:TVRD

$1.85 -0.03 (-1.60%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.87 +0.02 (+1.08%)

As of 09:04 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, AYTU, CLRB, and TVRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, AYTU, CLRB, and TVRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, AYTU, CLRB, and TVRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, AYTU, CLRB, and TVRD Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Cellectar Biosciences NASDAQ:CLRB

Cadrenal Therapeutics NASDAQ:CVKD

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, AYTU, CLRB, and TVRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, AYTU, CLRB, and TVRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, AYTU, CLRB, and TVRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, AYTU, CLRB, and TVRD Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Cellectar Biosciences NASDAQ:CLRB

Cadrenal Therapeutics NASDAQ:CVKD

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools